Dore, M.P.; Tomassini, G.; Rocchi, C.; Bulajic, M.; Carta, M.; Errigo, A.; Dimaggio, A.; Padedda, F.; Pes, G.M.
Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study. J. Clin. Med. 2023, 12, 4797.
https://doi.org/10.3390/jcm12144797
AMA Style
Dore MP, Tomassini G, Rocchi C, Bulajic M, Carta M, Errigo A, Dimaggio A, Padedda F, Pes GM.
Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study. Journal of Clinical Medicine. 2023; 12(14):4797.
https://doi.org/10.3390/jcm12144797
Chicago/Turabian Style
Dore, Maria Pina, Giulia Tomassini, Chiara Rocchi, Milutin Bulajic, Monica Carta, Alessandra Errigo, Alberto Dimaggio, Federica Padedda, and Giovanni Mario Pes.
2023. "Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study" Journal of Clinical Medicine 12, no. 14: 4797.
https://doi.org/10.3390/jcm12144797
APA Style
Dore, M. P., Tomassini, G., Rocchi, C., Bulajic, M., Carta, M., Errigo, A., Dimaggio, A., Padedda, F., & Pes, G. M.
(2023). Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study. Journal of Clinical Medicine, 12(14), 4797.
https://doi.org/10.3390/jcm12144797